EGFR and cancer: On the basis of data from the Taiwan Cancer Registry, Chang et al. [21] reported increased survival of patients with lung adenocarcinoma in Taiwan, which is also attributable to EGFR inhibitors having been approved for treating adenocarcinoma since 2003 (Gefitinib) and 2007 (Erlotinib).